| Recruiting | Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Pati NCT06909110 | Jessie L. Alexander | Phase 1 / Phase 2 |
| Recruiting | Evaluation of CMV/EBV-CMI in Haploid HSCT NCT06554197 | The First Affiliated Hospital of Soochow University | — |
| Enrolling By Invitation | Anti-viral T-cell Therapy by Gamma Capture NCT06027879 | Paul Szabolcs | Phase 1 / Phase 2 |
| Completed | Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitam NCT07256431 | Centre Hospitalier Universitaire de Nīmes | — |
| Recruiting | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Part NCT05592626 | Marengo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | R-MVST Cells for Treatment of Viral Infections NCT05183490 | Columbia University | Phase 1 |
| Terminated | Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic C NCT05305040 | AlloVir | Phase 2 / Phase 3 |
| Recruiting | Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the NCT04989491 | University Hospital, Strasbourg, France | Phase 4 |
| Completed | Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic NCT04693637 | AlloVir | Phase 2 / Phase 3 |
| Recruiting | EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection NCT03266653 | New York Medical College | Phase 2 |
| Unknown | Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial NCT04507477 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal NCT03769467 | Atara Biotherapeutics | Phase 1 / Phase 2 |
| Recruiting | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymph NCT03258567 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Immunodeficiency for Severe Epstein-Barr Virus Infection NCT03374566 | Children's Hospital of Fudan University | — |
| Completed | Early Detection of Epstein-Barr Virus Related Disease. NCT03546101 | University of Aarhus | — |
| Completed | Study on Infectious Mononucleosis in Munich NCT06002802 | Technical University of Munich | — |
| Completed | A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin NCT02715752 | The Center for the Biology of Chronic Disease | — |
| Completed | A Study of the Safety and Efficacy of EBV Specific T-cell Lines NCT02580539 | Dr. Jean-Sebastien Delisle, MD, PhD | Phase 1 / Phase 2 |
| Completed | Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents NCT02335437 | University Hospital, Akershus | — |
| Completed | ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation NCT01972035 | University of Minnesota | Phase 2 |
| Completed | A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma NCT01800071 | Cancer Research UK | Phase 1 |
| Completed | Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV NCT01535885 | Medical College of Wisconsin | Phase 1 |
| Completed | Bortezomib Plus Rituximab for EBV+ PTLD NCT01058239 | Massachusetts General Hospital | Phase 2 |
| Completed | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) NCT01070797 | Baylor College of Medicine | Phase 1 |
| Unknown | The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) i NCT01248598 | Rambam Health Care Campus | — |
| Completed | Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residu NCT01094405 | Chinese University of Hong Kong | Phase 2 |
| Completed | Modified Vaccinia Ankara (MVA) Vaccine Study NCT01256853 | Chinese University of Hong Kong | Phase 1 |
| Completed | Surveillance Study of Viral Infections Following Lung Transplantation NCT00701922 | Hannover Medical School | — |
| Completed | Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations NCT00070785 | National Institutes of Health Clinical Center (CC) | — |
| Completed | EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients NCT00963248 | Klinik für Kinder- und Jugendmedizin | — |
| Completed | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Spe NCT00058604 | Baylor College of Medicine | Phase 1 |
| Completed | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) NCT00058591 | Baylor College of Medicine | Phase 1 |
| Completed | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts NCT00058812 | Baylor College of Medicine | Phase 1 |